BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: a pilot study in a Chinese cohort

Deranged metabolic profiles and insulin resistance (IR) have been documented in patients with prolactinomas. Few data are yet available on the apolipoprotein (apo) B/apoA-I ratio and its relationship with IR in patients with prolactinomas. This study was aimed to evaluate the level of apoB/apoA-I ra...

Full description

Saved in:
Bibliographic Details
Published in:Tumor biology 2013-04, Vol.34 (2), p.1171-1176
Main Authors: Jiang, Xiao-Bing, He, Dong-Sheng, Mao, Zhi-Gang, Fan, Xiang, Lei, Ni, Hu, Bin, Song, Bing-Bing, Zhu, Yong-Hong, Wang, Hai-Jun
Format: Article
Language:English
Subjects:
Adult
Apolipoprotein A-I - metabolism
Apolipoproteins
Apolipoproteins B - metabolism
Asian Continental Ancestry Group
Biomedical and Life Sciences
Biomedicine
Body Mass Index
Cancer Research
Cohort Studies
Female
Follow-Up Studies
Hormones
Humans
Insulin Resistance
Lipids - analysis
Male
Metabolome
Pilot Projects
Pituitary gland
Prognosis
Prolactinoma - complications
Research Article
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Deranged metabolic profiles and insulin resistance (IR) have been documented in patients with prolactinomas. Few data are yet available on the apolipoprotein (apo) B/apoA-I ratio and its relationship with IR in patients with prolactinomas. This study was aimed to evaluate the level of apoB/apoA-I ratio and its association with IR in a Chinese subgroup with prolactinomas. Twenty-three prolactinoma patients and 20 healthy controls were enrolled in this study. The clinical anthropometric parameters and laboratory evaluation were collected. Insulin sensitivity was estimated using homeostatic model assessment [homeostasis model assessment of insulin resistance (HOMA-IR)]. Waist circumference and body weight index (BMI) were significantly higher in patients with prolactinomas than those in the controls ( p  
ISSN:1010-4283
1423-0380
DOI:10.1007/s13277-013-0660-z